The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score

Anticancer Research

Volumn 19, Issue 4 B, 1999, Pages 2821-2829

  Sinha, Akhouri A ^a,c,e   Quast, Barry J ^a   Korkowski, Joan C ^a   Wilson, Michael J ^a,b,c   Reddy, Pratap K ^c   Ewing, Stephen L ^b,c   Sloane, Bonnie F ^d   Gleason, Donald F ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VA MEDICAL CENTER   (United States)

Author keywords

Aggressive phenotype; Antisense probes; Cathepsin B; Gleason grading system; Gleason histological scores; Image analysis; In situ hybridization; Less aggressive phenotype; Prostate cancer; Stefin A cystatin A

Indexed keywords

CATHEPSIN B; COMPLEMENTARY DNA; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; RIBONUCLEASE; STEFIN A;

ARTICLE; CANCER GRADING; CANCER INVASION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA HYBRIDIZATION; DNA PROBE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY;

ADENOCARCINOMA; BASE SEQUENCE; CATHEPSIN B; CYSTATINS; DNA PRIMERS; HUMANS; IN SITU HYBRIDIZATION; MALE; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 0033452556     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Sinha AA, Gleason DF, DeLeon OF, Wilson MJ and Sloane BF: Localization of a biotinylated cathepsin B oligonucleotide probe in human prostate including invasive cells and invasive edges by in situ hybridization. Anat Rec 235: 233-240, 1993.
2. Wolf JSJ, Shinohara K, Carroll PR and Narayan P: Combined role of transrectal ultrasonography, Gleason score, and prostate-specific antigen in predicting organ-confined prostate cancer. Urology 42: 131-137, 1993.
3. Scardino PT, Weaver R and Hudson M: Early detection of prostate cancer. Hum Pathol 23: 211-222, 1992.
4. Mettlin C: The American cancer society National Prostate Cancer detection project and national patterns. CA Cancer J Clin 47: 261-264, 1997.
5. Coley CM, Barry MJ, Fleming C and Mulley AG: Early detection of prostate cancer, Part 1: Prior probability and effectiveness of tests. Ann Intern Med 126: 394-406, 1997.
6. Gleason DF: Histologic grading of prostate cancer. Hum Pathol 23: 273-279, 1992.
7. Gleason DF and Vacurg: Histologic grading and clinical staging of prostatic carcinoma. In Urologic pathology: the prostate (Tannenbaum M, ed) Lea & Febiger, Philadelphia, PA 171-213, 1977.
8. Grignon DJ and Hammond EH: College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors: report of the prostate cancer working group. Arch Pathol Lab Med 119: 1122-1126, 1995.
9. Murphy GP and Whitmore WFJ: A report of the workshops on the current status of the histologic grading of prostate cancer. Cancer 44: 1490-1494, 1979.
10. Epstein JI, Partin AW, Sauvageot J and Walsh PC: Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up. Amer J Surg Pathol 20: 286-292, 1996.
11. Epstein JI, Pizov G and Walsh PC: Correlation of pathologic-findings with progression after radical retropubic prostatectomy. Cancer 71: 3582-3593, 1993.
12. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI and Walsh PC: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150: 110-114, 1993.
13. Denmeade SR and Isaacs JT: Prostate cancer: Where are we and where are we going. Brit J Urol 79: 2-7, 1997.
14. Green GA, Hanlon AL, Al-Saleem T and Hanks GE: A Gleason score of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy. Cancer 83: 971-976, 1998.
15. Calkins CC, Sameni M, Koblinski J and Sloane BF: Differential localization of cysteine protease inhibitors and a target cysteine protease, cathepsin B, by immuno-confocal microscopy. J Histochem Cytochem 46: 745-751, 1998.
16. Yan S, Sameni M and Sloane BF: Cathepsin B and human tumor progression. Biol Chem 379: 113-123, 1998.
17. Kuopio T, Kankaaranta A, Jalava P, Kronqvist P, Kotkansalo T, Weber E and Collan Y: Cysteine prtoteinase inhibitor cystatin A in breast cancer. Cancer Res 58: 432-436, 1998.
18. Lah T, Kos J, Blejec A, Frkovic-Georgio S, Golouh R, Vrhovec I and Turk V: The expression of lysosomal proteinases and their inhibitors in breast cancer:possible relationship to prognosis of the disease. Pathol Oncol Res 3: 89-99, 1997.
19. Elliott E and Sloane BF: The cysteine protease cathepsin B in cancer. Perspectives in Drug Discovery and Design, 6: 12-32, 1996.
20. Sinha AA, MJ Wilson, DF Gleason, PK Reddy, M Sameni, BF Sloane: Immunohistochemical localization of cathepsin B in neoplastic human prostate. The Prostate 26: 171-178, 1995.
21. Sloane BF, Moin K, Krepela E and Rozhin J: Cathepsin B and its endogenous inhibitors: role in tumor malignancy. Cancer Metastasis Rev 9: 333-352, 1990.
22. Sloane BF, Moin K and Lah TT: Regulation of lysosomal endopeptidases in malignant neoplasia. In Biochemical and Molecular Aspects of Selected Cancers, Volume 2, 411-466, 1994.
23. Sloane BF, Sameni M, Cao L, Berquin I, Rozhin J, Ziegler G, K. Moin and Day N: Alterations in processing and trafficking of cathepsin B during malignant progression. In: Katunuma N, Suzuki K, Travis J, Fritz H, eds. Biological Functions of Proteases and Inhibitors. Japan Sci Societies Press, Tokyo, pp 131-147, 1994.
24. Murnane MJ, Sheahan K, Ozdemirji M and Shuja S: Stage specific increase in cathepsin B messenger RNA content in human colorectal carcinoma. Cancer Res 51: 1137-1142, 1991.
25. Sivaparvati M, Sawaya R, Wang SW, Rayford A, Yamamoto M, Liotta LA, Nicolson GL and Rao JS: Overexpression and localization of cathepsin B during the progression of human gliomas, Clin Exp Metastasis 13: 49-56, 1995.
26. Campo E, Munoz J, Miquel R, Palcin A, Cardesa A, Sloane BF and Emmert-Buck MR: Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am. J Pathol 145: 301-309, 1994.
27. Soderstrom K-O, Laato M, Wu P, Hopsu-Havu VK, Nurmi M and Rinne A: Expression of acid cysteine proteinase inhibitor (ACPI) in the normal human prostate, benign prostatic hyperplasia and adenocarcinoma. Int J Cancer 62: 1-4, 1995.
28. Lah TT, Kokalj-Kunovar M, Strukelj B, Pungercar J, Barlic-Maganja D, Drobnic-Kosorok M, Kastelic L, Babnik J, Golouh R and Turk V: Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int. J Cancer 50: 36-44, 1992.
29. Fong D, Calhoun DH, Hsieh WT, Lee B and Wells RD: Isolation of cDNA clone for the human lysosomal proteinase cathepsin B. Proc Natl Acad Sci U.S.A. 83: 2909-2913, 1986.
30. Kartasova T, Cornelissen BJC, Belt P and van de Putte P: Effects of UV, 4-NQO and TPA on gene expression in cultured human epidermal keratinocytes. Nuclei Acids Res 15: 5945-5962, 1987.
31. Davis LG, Dibner MD and F Batley J: Basic Methods in Molecular Biology. Elsevier Science, New York, 1986.
32. Sinha AA, Quast BJ, Wilson MJ, Reddy PK, Fernandes ET, Ewing SL and Gleason DF: Immunocytochemical localization of an immunoconjugate (antibody IgG against prostatic acid phosphatase conjugated to 5-fluoro-2′-deoxyuridine) in human prostate tumors. Anticancer Research 18: 1385-1392, 1998.
33. Buck MR, Karustis DG, Day NA, Honn KV and Sloane BF: Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J 282: 273-278, 1992.